CI-1017, a functionally M1-selective muscarinic agonist: Design, synthesis, and preclinical pharmacology

Pharmaceutica Acta Helvetiae

Volumn 74, Issue 2-3, 2000, Pages 141-148

  Tecle, H ^a   Schwarz, R D ^a   Barrett, S D ^a   Callahan, M J ^a   Caprathe, B W ^a   Davis, R E ^a   Doyle, P ^a   Emmerling, M ^a   Lauffer, D J ^a   Mirzadegan, T ^a   Moreland, D W ^a   Lipiniski, W ^a   Nelson, C ^a   Raby, C ^a   Spencer, C ^a   Spiegel, K ^a   Thomas, A J ^a   Jaen, J C ^a  

^a PFIZER INC   (United States)

Author keywords

A ; AD; Alzheimer's disease; APP; CI 1017; Cognitive disorders; Emotional and cognitive functions; M1 selective muscarinic agonist; Muscarinic receptor subtypes (M1 M5); Tecle H

Indexed keywords

1 AZABICYCLO[2.2.1]HEPTAN 3 ONE DERIVATIVE; 1 AZABICYCLO[2.2.1]HEPTAN 3 ONE O [3 (3' METHOXYPHENYL) 2 PROPYNYL]OXIME MALEATE; 2 ETHYL 8 METHYL 2,8 DIAZASPIRO[4.5]DECANE 1,3 DIONE; [4 [(3 CHLOROPHENYL)CARBAMOYLOXY] 2 BUTYNYL]TRIMETHYLAMMONIUM; AMYLOID BETA PROTEIN; ARECOLINE; ATROPINE; BETHANECHOL; CARBACHOL; L 670207; MUSCARINE; MUSCARINIC AGENT; MUSCARINIC M1 RECEPTOR; MUSCARINIC RECEPTOR; OTENZEPAD; OXOTREMORINE; PIRENZEPINE; QUINUCLIDINYL BENZILATE; RECEPTOR SUBTYPE; SCOPOLAMINE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; CELL METABOLISM; CONFERENCE PAPER; DOSE RESPONSE; DRUG DESIGN; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SYNTHESIS; HIPPOCAMPUS; HUMAN; NONHUMAN; PROTEIN STRUCTURE; SPATIAL MEMORY; STRUCTURE ACTIVITY RELATION;

ANIMALS; BICYCLO COMPOUNDS, HETEROCYCLIC; CLONING, MOLECULAR; HUMANS; MALE; MAZE LEARNING; MEMORY; MICE; MICE, INBRED C57BL; MUSCARINIC AGONISTS; OXIMES; RATS; RECEPTOR, MUSCARINIC M1; RECEPTORS, MUSCARINIC; SECOND MESSENGER SYSTEMS;

EID: 0034126026     PISSN: 00316865     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0031-6865(99)00027-8     Document Type: Conference Paper

References (29)

1. Baker, R., Saunders, J., 1989. Central muscarinic ligands and receptors. In: Allen, R.C. (Eds.), Annu. Rep. Med. Chem., Vol. 24, pp. 31-40 and references therein.
2. Bolden C.et al. Antagonism by antimuscarinic and neuroleptic compounds at the five cloned human muscarinic cholinergic receptors expressed in Chinese hamster ovary cells. J. Pharmacol. Exp. Ther. 517:1992;576-580.
3. Bonner T.I.et al. Identification of a family of muscarinic acetylcholine receptor genes. Science. 237:1987;527-532.
4. Braeuner-Osborne H. Annulated heterocyclic bioisosteres of norarecoline. Synthesis and molecular pharmacology at five recombinant human muscarinic acetylcholine receptors. J. Med. Chem. 38:1995;2188-2195.
5. 5): high throughput assays in mammalian cells. Eur. J. Pharmacol. 295:1996;93-102.
6. Buckley, N.J., 1990. Molecular pharmacology of cloned muscarinic receptors. In: Nahorski, S.R., (Ed.), Transmembrane Signaling, Intercellular Messengers and Implications for Drug Development. Wiley, pp. 11-31.
7. Buckley N.J.et al. Antagonist binding properties of five cloned muscarinic receptors expressed in CHO-K1 cells. Mol. Pharmacol. 35:1989;469-476.
8. Christie J.E.et al. Physostigmine and arecoline: effects of intravenous infusions in Alzheimer presenile dementia. Br. J. Psychiatry. 138:1981;46-50.
9. Davies P., Maloney A. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet. 2:1976;1403.
10. Davis, R., et al., 1993. Subtype-selective muscarinic agonists: potential therapeutic agents for Alzheimer's disease. In: Cuello, C.A., (Ed.), Cholinergic Function and Dysfunction, Progress in Brain Research. Elsevier, Amsterdam, pp. 439-445.
11. Doerje F.et al. Antagonist binding profiles of five cloned human muscarinic receptor subtypes. Pharmacol. Exp. Ther. 256:1991;727-733.
12. 1 muscarinic receptor to β-amyloid precursor protein secretion. J. Neurochem. 7:1998;2094-2103.
13. Hulme E.C.et al. Muscarinic receptor subtypes. Annu. Rev. Pharmacol. Toxicol. 30:1990;633-673.
14. Jones, S.V.P., et al., 1992. Muscarinic acetylcholine receptors. In: Brann, M.R. (Ed.), Molecular Biology of G-Protein Receptors. Birkhauser, Boston, pp. 170-197.
15. McConnell H.M. The cytosensor microphysiometer: biological applications of silicon technology. Science. 257:1992;1906-1912.
16. Mutschler E., Hultzsch K. Uber struktur-wirkungs-beziehungen von ungesattigten estern des arecaidins und dihydroarecaidins. Arsneim-Forsch. (Drug Res.). 23:1973;732-737.
17. Nabeshima T.et al. Staurosporine facilitates recovery from the basal forebrain-lesion-induced impairment of learning and deficit of cholinergic neuron in rats. J. Pharmacol. Exp. Ther. 257:1991;562-566.
18. Perry E.K.et al. Correlation of cholinergic abnormalities with senile plaques and mental test scores in dementia. Br. Med. J. 2:1978;1457-1459.
19. Robertson M.C., Harrell L.E. Cholinergic activity and amyloid precursor protein metabolism. Brain Res. Rev. 25:1997;50-69.
20. Schwarz R.D. Characterization of muscarinic agonists in recombinant cell lines. Life Sci. 52:1993;465-472.
21. Street L.J.et al. Synthesis and biological activity of 1,2,4,-oxadiazole derivatives: highly potent and efficacious agonists for cortical muscarinic receptors. J. Med. Chem. 33:1990;2690-2697.
22. Symons J.P.et al. Water maze learning and effects of cholinergic drugs in mouse strains with high and low hippocampal pyramidal cell counts. Life Sci. 42:1988;375-383.
23. Tecle, H., et al., 1989. Abstract of papers. 197th National Meeting of the American Chemical Society, Dallas, TX. American Chemical Society, Washington, DC, MEDI-47.
24. Tecle H.et al. Synthesis and SAR of bulky 1-azabicyclo[2.2.1]-3-one oximes as muscarinic receptor-subtype-selective agonists. Life Sci. 52:1993;505.
25. Venter, J.C., Fraser, C.M., 1990. Molecular biology of receptors and drug design. In: Clark, C.R., Moos, W.H. (Eds.), Drug Discovery Technologies. Ellis Horwood, Chichester, pp. 231-255.
26. 3H ]-cis-methyldioxolane J. Pharmacol. Exp. Ther. 229:1984;747-755.
27. 3H ]quinuclidinyl benzilate binding to rat cerebral cortical and cardiac muscarinic cholinergic sites: I. Characterization and regulation of agonist binding to putative muscarinic subtypes J. Pharmacol. Exp. Ther. 237:1986;411-418.
28. Whishaw I.Q.et al. Disruption of central cholinergic systems in the rat basal forebrain lesions or atropine: effects on feeding, sensorimotor behavior, locomotor activity and spatial navigation. Behav. Brain Res. 17:1985;103-115.
29. Whitehouse P.et al. Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science. 215:1982;1237-1239.